Our next step is Xofigo.
Hubby had been through 10 sessions of docetaxel in 2021 where PSA went down to 1.1 (previously 117 at start of chemo). He got a break from it for 2 months, but it climbed back up to 46.8 and had to go back on docetaxel again. It didn't work as well as last time - his PSA never got below 24. He's had an additional 14 sessions this second time around with his PSA climbing with every session (the last four: 49.01, 59.06, 65.64 & 78.69 yesterday). We changed MO's a couple of months ago. Our previous doc referred us as he didn't know what else he could do for us. Our new doc felt Xofigo would be a better way to go. But we all pivoted when Lu177 was approved by FDA. He felt continuing on with docetaxel until we could get Lu177 made sense. Until it doesn't. The supply issues etc etc with Lu177 have made this feel like it could be months or longer. Our MO's concern is being able to receive Lu177 after Xofigo. There seems to be uncertainty with how long you need to wait between those 2 treatments. He thought it would be a year. If at all. There's still Jevtana that we haven't tried. Our MO would rather save that for use after Xofigo. CT scans and bone scans will be scheduled again next week. Just had them in January. Metastatic throughout the entire skeleton but no organ or soft tissue infiltration.
Was on abiraterone and then Xtandi after that failed. Didn't get much time out of either of those. Still continuing with Xgeva & Lupron every 3 months.
He has tolerated chemo, although it's been cumulative and his "bad" days have been increasing harder on him. My hope is that he'll tolerate Xofigo well. I know we'll have to watch his blood counts through this. We've had genetic testing through Foundation One twice. Most recently a couple of months ago. No actionable mutations were found.
Any feedback on this plan is appreciated. Thank you my people!